Total Payments
$154,891
2024 Payments
$13,574
Companies
23
Transactions
255
Medicare Patients
827
Medicare Billing
$78,691
Payment Breakdown by Category
Other$138,449 (89.4%)
Food & Beverage$8,044 (5.2%)
Travel$5,123 (3.3%)
Consulting$3,140 (2.0%)
Education$135.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $96,439 | 38 | 62.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $24,600 | 11 | 15.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,760 | 5 | 8.2% |
| Food and Beverage | $8,044 | 164 | 5.2% |
| Travel and Lodging | $5,123 | 22 | 3.3% |
| Honoraria | $4,650 | 9 | 3.0% |
| Consulting Fee | $3,140 | 2 | 2.0% |
| Education | $135.64 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $56,692 | 79 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $34,452 | 33 | $0 (2023) |
| ABBVIE INC. | $30,390 | 54 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $13,302 | 6 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $6,855 | 7 | $0 (2017) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6,265 | 5 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $4,940 | 4 | $0 (2017) |
| Janssen Biotech, Inc. | $1,056 | 36 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $210.58 | 9 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $145.28 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,574 | 18 | Ipsen Biopharmaceuticals, Inc ($13,302) |
| 2023 | $6,224 | 29 | Gilead Sciences, Inc. ($4,544) |
| 2022 | $12,652 | 25 | INTERCEPT PHARMACEUTICALS, INC. ($6,107) |
| 2021 | $17,840 | 21 | Intercept Pharmaceuticals, Inc. ($9,512) |
| 2020 | $12,897 | 20 | Gilead Sciences, Inc. ($7,475) |
| 2019 | $26,852 | 47 | AbbVie, Inc. ($14,885) |
| 2018 | $26,399 | 44 | Gilead Sciences, Inc. ($8,759) |
| 2017 | $38,452 | 51 | Gilead Sciences Inc ($14,659) |
All Payment Transactions
255 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $26.10 | General |
| Category: Immunology | ||||||
| 11/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,308.00 | General |
| Category: Rare Disease | ||||||
| 10/24/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $118.58 | General |
| Category: Rare Disease | ||||||
| 10/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Immunology | ||||||
| 08/13/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,308.00 | General |
| Category: Rare Disease | ||||||
| 08/13/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $135.52 | General |
| Category: Rare Disease | ||||||
| 07/11/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,308.00 | General |
| Category: Rare Disease | ||||||
| 07/11/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $123.72 | General |
| Category: Rare Disease | ||||||
| 05/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: IMMUNOLOGY | ||||||
| 05/20/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: Immunology | ||||||
| 05/09/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: Immunology | ||||||
| 04/22/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Immunology | ||||||
| 04/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.25 | General |
| 03/26/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $28.13 | General |
| 02/28/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Immunology | ||||||
| 11/14/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Immunology | ||||||
| 11/13/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $1.67 | General |
| 11/11/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $160.11 | General |
| 11/10/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.08 | General |
| 09/28/2023 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
| 08/30/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.23 | General |
| 08/16/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $39.98 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 264 | 287 | $105,709 | $24,648 |
| 2022 | 7 | 163 | 180 | $68,489 | $17,517 |
| 2021 | 8 | 249 | 275 | $91,792 | $23,835 |
| 2020 | 8 | 151 | 169 | $62,215 | $12,691 |
Total Patients
827
Total Services
911
Medicare Billing
$78,691
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 39 | 39 | $29,001 | $7,403 | 25.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 53 | $12,056 | $3,243 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 32 | 37 | $13,762 | $2,868 | 20.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 26 | $10,028 | $2,656 | 26.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 30 | 30 | $12,142 | $2,435 | 20.1% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 28 | 28 | $7,028 | $1,779 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 30 | $7,938 | $1,679 | 21.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $5,747 | $1,426 | 24.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $6,473 | $806.64 | 12.5% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 17 | 17 | $1,534 | $352.21 | 23.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 31 | 31 | $23,002 | $6,240 | 27.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 31 | 32 | $12,491 | $3,329 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 39 | $14,334 | $3,281 | 22.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 34 | $6,967 | $1,873 | 26.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 15 | 15 | $6,015 | $1,419 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 18 | $4,668 | $1,127 | 24.1% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 11 | 11 | $1,012 | $249.26 | 24.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 54 | 54 | $20,574 | $5,766 | 28.0% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 29 | 29 | $20,880 | $5,736 | 27.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 51 | 69 | $13,869 | $3,765 | 27.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 41 | $15,170 | $3,599 | 23.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 34 | 37 | $9,657 | $2,340 | 24.2% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 14 | 14 | $5,488 | $1,220 | 22.2% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 13 | 13 | $4,498 | $1,004 | 22.3% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 18 | 18 | $1,656 | $405.28 | 24.5% |
About Dr. Michael Babich, MD
Dr. Michael Babich, MD is a Gastroenterology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1598764458.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Babich, MD has received a total of $154,891 in payments from pharmaceutical and medical device companies, with $13,574 received in 2024. These payments were reported across 255 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($96,439).
As a Medicare-enrolled provider, Babich has provided services to 827 Medicare beneficiaries, totaling 911 services with total Medicare billing of $78,691. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Pittsburgh, PA
- Active Since 07/21/2005
- Last Updated 12/05/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1598764458
Products in Payments
- Epclusa (Drug) $49,716
- OCALIVA (Drug) $29,042
- Mavyret (Drug) $21,412
- IQIRVO (Drug) $13,302
- XIFAXAN (Drug) $11,206
- ZEPATIER (Drug) $6,789
- OCA (Drug) $5,410
- Vosevi (Drug) $3,971
- MAVYRET (Drug) $2,644
- Vemlidy (Drug) $2,060
- STELARA (Biological) $823.72
- ENTYVIO (Biological) $178.39
- TREMFYA (Drug) $165.43
- TERLIVAZ (Drug) $145.28
- INFINITY (Device) $144.81
- REMICADE (Biological) $66.62
- VIBERZI (Drug) $40.81
- LINZESS (Drug) $39.46
- Mulpleta (Drug) $38.11
- Entyvio (Biological) $32.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Pittsburgh
Dr. Sandra El-Hachem, Md, MD
Gastroenterology — Payments: $416,688
Gastroenterology $416,688
Elie Aoun, M.d., M.s, M.D., M.S
Gastroenterology — Payments: $358,981
Gastroenterology $358,981
Randall Brand
Gastroenterology — Payments: $111,530
Gastroenterology $111,530
Gursimran Kochhar, Md, MD
Gastroenterology — Payments: $109,305
Gastroenterology $109,305
Dr. Heitham Abdul-Baki, M.d, M.D
Gastroenterology — Payments: $67,965
Gastroenterology $67,965
Dr. Katie Farah, Md, MD
Gastroenterology — Payments: $60,366
Gastroenterology $60,366